KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to -$400000.0.

  • Emergent BioSolutions' Gains from Investment Securities changed N/A to -$400000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year decrease of 317.46%. This contributed to the annual value of -$6.5 million for FY2024, which is 18024.69% down from last year.
  • Latest data reveals that Emergent BioSolutions reported Gains from Investment Securities of -$400000.0 as of Q3 2025.
  • In the past 5 years, Emergent BioSolutions' Gains from Investment Securities ranged from a high of $18.9 million in Q4 2022 and a low of -$2.6 million during Q4 2024
  • Over the past 5 years, Emergent BioSolutions' median Gains from Investment Securities value was $750000.0 (recorded in 2021), while the average stood at $3.0 million.
  • As far as peak fluctuations go, Emergent BioSolutions' Gains from Investment Securities soared by 620000.0% in 2022, and later tumbled by 230000.0% in 2025.
  • Over the past 5 years, Emergent BioSolutions' Gains from Investment Securities (Quarter) stood at $300000.0 in 2021, then soared by 6200.0% to $18.9 million in 2022, then crashed by 83.6% to $3.1 million in 2023, then tumbled by 183.87% to -$2.6 million in 2024, then soared by 84.62% to -$400000.0 in 2025.
  • Its Gains from Investment Securities was -$400000.0 in Q3 2025, compared to -$2.2 million in Q2 2025 and $11.3 million in Q1 2025.